Underutilization of β-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures

Circulation: Cardiovascular Quality and Outcomes

Volumn 3, Issue 2, 2010, Pages 204-211

  Hauptman, Paul J ^a,b   Swindle, Jason P ^b   Masoudi, Frederick A ^c,d   Burroughs, Thomas E ^b  

^a Washington University   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

Drugs; Heart failure; Prevention; Sudden death

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; AGING; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; DEFIBRILLATOR; DRUG USE; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTPATIENT CARE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CARDIAC PACING, ARTIFICIAL; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; DATABASES AS TOPIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DRUG PRESCRIPTIONS; DRUG UTILIZATION; ELECTRIC COUNTERSHOCK; FEMALE; GUIDELINE ADHERENCE; HEART FAILURE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POSTOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; PREOPERATIVE CARE; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953464098     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.109.880450     Document Type: Article

References (40)

1. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe, Part 2: treatment. Eur Heart J. 2003;24:464-474. (Pubitemid 36286188)
2. Muntwyler J, Cohen-Solal A, Freemantle N, Eastaugh J, Cleland JG, Follath F. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail. 2004;6:663-668.
3. Roe CM, Motheral BR, Teitelbaum F, Rich MW. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J. 1999;138:818-825.
4. Sheppard R, Behlouli H, Richard H, Pilote L. Effect of gender on treatment, resource utilization, and outcomes in congestive heart failure in Quebec, Canada. Am J Cardiol. 2005;95:955-959.
5. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61.
6. Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National patterns of use and effectiveness of angiotensin- converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724-731.
7. Patel P, White DL, Deswal A. Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. Am Heart J. 2007;153:515-522.
8. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006; 48: e247-e346.
9. Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:e1-e2.
10. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the Am College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112: e154-e235.
11. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
12. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF): MERIT-HF Study Group. JAMA. 2000;283:1295-1302.
13. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
14. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658. (Pubitemid 32479962)
15. Brodine WN, Tung RT, Lee JK, Hockstad ES, Moss AJ, Zareba W, Hall WJ, Andrews M, McNitt S, Daubert JP. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 2005;96:691-695.
16. Lai HM, Aronow WS, Kruger A, Desai H, Amin H, Frishman WH, Cohen M, Sorbera C. Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators. Am J Cardiol. 2008;102:77-78.
17. Tandri H, Griffith LS, Tang T, Nasir K, Zardkoohi O, Reddy CV, Capps M, Calkins H, Donahue JK. Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators. Heart Rhythm. 2006;3:762-768.
18. FDA. The National Drug Code Directory. November 3, 2008. Available at: http://www.fda.gov/cder/ndc/. Accessed December 2, 2008.
19. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-186.
20. National Committee for Quality Assurance. HEDIS 2008: National Drug Code List. November 15, 2008. Available at: http://www.ncqa.org/tabid/598/Default. aspx. Accessed January 2, 2009.
21. Makikallio TH, Huikuri HV. Association between usage of beta-blocking medication and benefit from implantable cardioverter therapy. Am J Cardiol. 2006;98:1245-1247.
22. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471-1480.
23. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
24. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
25. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
26. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
27. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549. (Pubitemid 40517094)
28. Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, Chong A, Stukel TA, Levy D, Laupacis A. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294:1240-1247.
29. Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation. 2005;111:179-185.
30. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 2004;291:1358-1367.
31. Ansari M, Shlipak MG, Heidenreich PA, Van Ostaeyen D, Pohl EC, Browner WS, Massie BM. Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation. 2003;107:2799-2804.
32. Hreybe H, Bedi M, Ezzeddine R, Barrington W, Jain S, Ngwu O, Saba S. Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers. Am Heart J. 2005; 150: 1064.
33. Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589-1595.
34. Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005;149:444-450.
35. Scherer M, Sobek C, Wetzel D, Koschack J, Kochen MM. Changes in heart failure medications in patients hospitalised and discharged. BMC Fam Pract. 2006;7:69-74.
36. Bello D, Shah NB, Edep ME, Tateo IM, Massie BM. Self-reported differences between cardiologists and heart failure specialists in the management of chronic heart failure. Am Heart J. 1999;138:100-107.
37. Chin MH, Friedmann PD, Cassel CK, Lang RM. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med. 1997;12:523-530.
38. Chin MH, Wang JC, Zhang JX, Lang RM. Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure: effect of physician specialty and patient characteristics. J Gen Intern Med. 1997;12:563-566.
39. Reis SE, Holubkov R, Edmundowicz D, McNamara DM, Zell KA, Detre KM, Feldman AM. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol. 1997;30:733-738.
40. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. J Card Fail. 2007;13:722-731.